CRO vs. university partnership: which is right for your brand?

Two paths exist for running a clinical trial as a health brand. The first is hiring a Contract Research Organisation (CRO): a commercial company whose job is to design, manage, and deliver your study to a defined scope and timeline. The second is partnering with a university: an academic institution that conducts the research through one of its departments.

Both can produce peer-reviewed, publishable evidence. The differences that actually matter for most brands are in speed, contractual control, IP ownership, and what happens when things change.

The short answer

For most health brands with a product to launch, a commercial deadline, or a retail buyer to impress, a CRO is the right choice. University partnerships make sense in specific circumstances: when you have a genuinely novel scientific question, a long runway, and no near-term commercial dependency on the timeline.

Here is how the two routes compare across the factors that matter most.

Timeline

CRO: 6 to 9 months from kick-off to first results. Contracts are processed in days. Ethics is submitted to an independent Research Ethics Committee and typically approved in 3 to 5 weeks. Recruitment begins immediately after approval using a pre-built participant network. Data collection and analysis run to a project plan with defined milestones.

University: 18 to 36 months, often longer. Commercial contracting with a university involves the institution's tech transfer or legal team, which operates on a different schedule to a commercial counterparty. It is common for contract negotiations alone to take 6 to 18 months. Ethics approval through a university committee adds another 2 to 6 months, because committees operate on monthly or bi-monthly review cycles. Data collection is then paced around academic calendars, researcher availability, and competing departmental priorities.

If you have a product launch or a retail buyer conversation on a specific timeline, the university route cannot reliably accommodate it.

Cost

CRO fees are visible and fixed. A commercially managed trial comes with a defined scope, a fixed-price contract, and milestone-based billing. You know what you are paying before you commit.

University partnerships often have a lower headline fee but higher total cost. The direct fee may be lower than a CRO quote, but that number rarely accounts for the internal time required to manage the relationship over 18 to 36 months. Liaison meetings, contract renegotiations, managing delays, and chasing deliverables add up. For a founder or marketing lead handling this alongside other responsibilities, the opportunity cost is real.

The all-in cost of a university trial, including internal management time, is often comparable to or higher than a CRO trial that completes in a fraction of the time. See our clinical trial cost guide for a breakdown of what drives price in each category.

IP ownership

With a CRO, the sponsor owns the IP. This is a contractual default in a well-structured CRO agreement. The data, the findings, and the right to use, publish, and commercialise the results belong to you.

With a university, IP ownership is negotiated and often contested. Most UK universities have institutional intellectual property policies that assert rights over innovations arising from work conducted using their facilities, staff, or resources. Depending on the agreement, this can include the study data, analytical methods, and any novel formulations identified during the research. Getting clean IP assignment from a university often requires negotiation before contracts are signed, which adds time and legal cost.

For any brand planning to use study findings in commercial claims, investor materials, or licensing arrangements, clean IP ownership is essential.

Publication control

With a CRO, publication timing is agreed upfront. The manuscript is prepared as part of the project deliverable, and submission is on your timeline. If you want to publish before a product launch, that is part of the plan.

With a university, the academic team controls publication. Universities exist to generate and publish knowledge. The researcher running your study has their own publication priorities, journal preferences, and academic career incentives. If the results are less commercially flattering than you hoped, publication may be deprioritised. If the researcher leaves, the manuscript may stall. There is rarely a contractual obligation to publish on a commercial timeline.

Scientific credibility

A common assumption is that university-run research is more credible than CRO-run research. This is not accurate.

What determines the credibility and publishability of a study is the study design, the statistical rigour, and the journal it is published in: not the institutional affiliation of the team that ran it. A well-designed RCT conducted by a CRO and published in a peer-reviewed journal carries the same evidential weight as one run by a university department.

The ASA applies this standard consistently. Regulatory bodies, retail buyers, and peer reviewers assess methodology and journal quality, not whether the work was academic or commercial.

When a university partnership might make sense

University partnerships suit a specific set of circumstances:

• You are conducting long-term research (3 to 5 years) with no near-term commercial dependency on the results.
• You want access to a specific academic institution's facilities or patient population that is not available elsewhere.
• You are applying for Innovate UK or similar grant funding that requires an academic partner.
• The scientific question is genuinely novel and benefits from the university's domain expertise.

In all other cases, a commercial CRO will deliver a faster, more predictable, and more commercially useful outcome.

Frequently asked questions